Literature DB >> 24643716

Tirosine kinase inhibitors adverse events.

Leonardo Campiotti1, Andrea Maresca, Luigina Guasti, Anna Maria Grandi.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24643716      PMCID： PMC3958466          DOI： 10.1634/theoncologist.2013-0397

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  4 in total

1.  Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.

Authors:  Ester M Orlandi; Barbara Rocca; Anna S Pazzano; Stefano Ghio
Journal:  Leuk Res       Date:  2011-09-03       Impact factor: 3.156

2.  Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.

Authors:  Makoto Sano; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hiroshi Satoh; Kazunori Ohnishi; Hideharu Hayashi
Journal:  Intern Med       Date:  2012-09-01       Impact factor: 1.271

Review 3.  Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.

Authors:  Daniel J Lenihan; Peter R Kowey
Journal:  Oncologist       Date:  2013-08-05

4.  Pulmonary arterial hypertension in patients treated by dasatinib.

Authors:  David Montani; Emmanuel Bergot; Sven Günther; Laurent Savale; Anne Bergeron; Arnaud Bourdin; Helene Bouvaist; Matthieu Canuet; Christophe Pison; Margareth Macro; Patrice Poubeau; Barbara Girerd; Delphine Natali; Christophe Guignabert; Frédéric Perros; Dermot S O'Callaghan; Xavier Jaïs; Pascale Tubert-Bitter; Gérard Zalcman; Olivier Sitbon; Gérald Simonneau; Marc Humbert
Journal:  Circulation       Date:  2012-03-26       Impact factor: 29.690
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.